CDXS has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
CDXS has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Codexis's change in receivables for the quarter that ended in Dec. 2023 was $0.00 Mil. It means Codexis's Accounts Receivable stayed the same from Sep. 2023 to Dec. 2023 .
Codexis's change in receivables for the fiscal year that ended in Dec. 2023 was $0.00 Mil. It means Codexis's Accounts Receivable stayed the same from Dec. 2022 to Dec. 2023 .
Codexis's Accounts Receivable for the quarter that ended in Dec. 2023 was $10.04 Mil.
Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Codexis's Days Sales Outstanding for the three months ended in Dec. 2023 was 34.48.
In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Codexis's liquidation value for the three months ended in Dec. 2023 was $24.04 Mil.
The historical data trend for Codexis's Change In Receivables can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Codexis Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Change In Receivables | Get a 7-Day Free Trial | -5.87 | - | - | - | - |
Codexis Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Change In Receivables | Get a 7-Day Free Trial | - | - | - | - | - |
Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.
Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Codexis (NAS:CDXS) Change In Receivables Explanation
1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
Codexis's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:
Days Sales Outstanding | |||||
= | Accounts Receivable | / | Revenue | * | Days in Period |
= | 10.036 | / | 26.561 | * | 91 |
= | 34.48 |
2. In Ben Graham's calculation of liquidation value, Codexis's accounts receivable are only considered to be worth 75% of book value:
Codexis's liquidation value for the quarter that ended in Dec. 2023 is calculated as:
Liquidation Value | |||||||
= | Cash, Cash Equivalents, Marketable Securities | - | Total Liabilities | + | (0.75 * Accounts Receivable) | + | (0.5 * Total Inventories) |
= | 65.116 | - | 49.946 | + | 0.75 * 10.036 | + | 0.5 * 2.685 |
= | 24.04 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Codexis's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.
Byron L Dorgan | director | C/O CODEXIS, INC., 200 PENOBSCOT DRIVE, REDWOOD CITY CA 94063 |
Kevin Norrett | officer: Chief Operating Officer | C/O SIERRA ONCOLOGY, INC., 1820 GATEWAY DRIVE, SUITE 110, SAN MATEO CA 94404 |
Margaret Nell Fitzgerald | officer: See Remarks | ALLAKOS INC., 825 INDUSTRIAL ROAD, SUITE 500, SAN CARLOS CA 94070 |
Sriram Ryali | officer: Chief Financial Officer | C/O EIGER BIOPHARMACEUTICALS, INC., 2155 PARK BLVD., PALO ALTO CA 94306 |
Stephen George Dilly | director, officer: See Remarks | C/O SIERRA ONCOLOGY, INC., 1820 GATEWAY DRIVE, SUITE 110, SAN MATEO CA 94404 |
John J Nicols | director, officer: President and CEO | ALBEMARLE CORP, 451 FLORIDA ST, BATON ROUGE LA 70801 |
H Stewart Parker | director | |
Rahul Singhvi | director | 246 HOLLY DRIVE, CHALFONT PA 18914 |
Dennis P Wolf | director | 1101 EAST MEADOW DR, PALO ALTO CA 94303 |
Patrick Y Yang | director | C/O GENENTECH INC, 1 DNA WAY,MS 49,ATTN:K.STRAND OR J.BERRY, SOUTH SAN FRANCISCO CA 94080-4990 |
Bernard J Kelley | director | |
Esther Martinborough | director | C/O CODEXIS, INC., 200 PENOBSCOT DRIVE, REDWOOD CITY CA 94063 |
Jennifer Aaker | director | C/O CODEXIS, INC., 200 PENOBSCOT DRIVE, REDWOOD CITY CA 94063 |
Alison Moore | director | C/O ALLOGENE THERAPEUTICS, INC., 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080 |
Thomas R Baruch | director | 1 LETTERMAN DRIVE, BUILDING C, SUITE CM500, SAN FRANCISCO CA 94129 |
From GuruFocus
By Marketwired • 07-31-2023
By Marketwired • 11-03-2023
By Value_Insider Value_Insider • 11-16-2022
By sperokesalga sperokesalga • 02-27-2023
By Marketwired • 07-20-2023
By Value_Insider Value_Insider • 11-29-2022
By Marketwired • 10-19-2023
By Marketwired • 10-27-2023
By sperokesalga sperokesalga • 04-20-2023
By Marketwired • 10-26-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.